Analysts Offer Insights on Healthcare Companies: Oragenics (NYSE MKT: OGEN) and Audentes Therapeutics (NASDAQ: BOLD)

By Austin Angelo

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Oragenics (OGENResearch Report) and Audentes Therapeutics (BOLDResearch Report).

Oragenics (OGEN)

H.C. Wainwright analyst Yi Chen reiterated a Buy rating on Oragenics today and set a price target of $2.00. The company’s shares closed last Monday at $0.61.

According to TipRanks.com, Chen ‘s ranking currently consits of no stars on a 0-5 ranking scale, with an average return of -10.2% and a 35.3% success rate. Chen covers the Healthcare sector, focusing on stocks such as HTG Molecular Diagnostics, EyePoint Pharmaceuticals, and Stealth Biotherapeutics.

Oragenics has an analyst consensus of Moderate Buy, with a price target consensus of $2.00.

See today’s analyst top recommended stocks >>

Audentes Therapeutics (BOLD)

H.C. Wainwright analyst Debjit Chattopadhyay maintained a Hold rating on Audentes Therapeutics today and set a price target of $60.00. The company’s shares closed last Monday at $28.61.

According to TipRanks.com, Chattopadhyay is a 1-star analyst with an average return of -1.6% and a 44.0% success rate. Chattopadhyay covers the Healthcare sector, focusing on stocks such as Global Blood Therapeutics, Precision BioSciences, and Sarepta Therapeutics.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Audentes Therapeutics with a $57.50 average price target, representing a 94.8% upside. In a report released today, Robert W. Baird also upgraded the stock to Hold with a $60.00 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.